Distribution  ||| S:0 E:13 ||| NN
of  ||| S:13 E:16 ||| IN
primary  ||| S:16 E:24 ||| JJ
immunodeficiency  ||| S:24 E:41 ||| JJ
disorders  ||| S:41 E:51 ||| NNS
diagnosed  ||| S:51 E:61 ||| VBN
in  ||| S:61 E:64 ||| IN
a  ||| S:64 E:66 ||| DT
tertiary  ||| S:66 E:75 ||| JJ
referral  ||| S:75 E:84 ||| NN
center ||| S:84 E:90 ||| NN
, ||| S:90 E:91 ||| ,
Tehran ||| S:91 E:97 ||| NNP
,  ||| S:97 E:99 ||| ,
Iran  ||| S:99 E:104 ||| NNP
( ||| S:104 E:105 ||| -LRB-
2006-2013 ||| S:105 E:114 ||| NNP
)  ||| S:114 E:116 ||| -RRB-
Primary  ||| S:116 E:124 ||| JJ
immunodeficiency  ||| S:124 E:141 ||| JJ
disorders  ||| S:141 E:151 ||| NNS
( ||| S:151 E:152 ||| -LRB-
PID ||| S:152 E:155 ||| NNP
)  ||| S:155 E:157 ||| -RRB-
are  ||| S:157 E:161 ||| VBP
a  ||| S:161 E:163 ||| DT
group  ||| S:163 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
hereditary  ||| S:172 E:183 ||| JJ
disorders  ||| S:183 E:193 ||| NNS
characterized  ||| S:193 E:207 ||| VBN
by  ||| S:207 E:210 ||| IN
an  ||| S:210 E:213 ||| DT
increased  ||| S:213 E:223 ||| JJ
susceptibility  ||| S:223 E:238 ||| NN
to  ||| S:238 E:241 ||| TO
severe  ||| S:241 E:248 ||| JJ
and  ||| S:248 E:252 ||| CC
recurrent  ||| S:252 E:262 ||| JJ
infections ||| S:262 E:272 ||| NNS
,  ||| S:272 E:274 ||| ,
autoimmunity ||| S:274 E:286 ||| NN
,  ||| S:286 E:288 ||| ,
lymphoproliferative  ||| S:288 E:308 ||| JJ
disorders ||| S:308 E:317 ||| NNS
,  ||| S:317 E:319 ||| ,
and  ||| S:319 E:323 ||| CC
malignancy ||| S:323 E:333 ||| NN
.  ||| S:333 E:335 ||| .
To  ||| S:335 E:338 ||| TO
evaluate  ||| S:338 E:347 ||| VB
the  ||| S:347 E:351 ||| DT
demographic  ||| S:351 E:363 ||| JJ
and  ||| S:363 E:367 ||| CC
clinical  ||| S:367 E:376 ||| JJ
data  ||| S:376 E:381 ||| NNS
of  ||| S:381 E:384 ||| IN
PID  ||| S:384 E:388 ||| NNP
patients  ||| S:388 E:397 ||| NNS
diagnosed  ||| S:397 E:407 ||| VBN
in  ||| S:407 E:410 ||| IN
a  ||| S:410 E:412 ||| DT
referral  ||| S:412 E:421 ||| JJ
pediatric  ||| S:421 E:431 ||| JJ
hospital ||| S:431 E:439 ||| NN
.  ||| S:439 E:441 ||| .
All  ||| S:441 E:445 ||| DT
PID  ||| S:445 E:449 ||| NNP
cases  ||| S:449 E:455 ||| NNS
with  ||| S:455 E:460 ||| IN
a  ||| S:460 E:462 ||| DT
confirmed  ||| S:462 E:472 ||| JJ
diagnosis ||| S:472 E:481 ||| NN
,  ||| S:481 E:483 ||| ,
according  ||| S:483 E:493 ||| VBG
to  ||| S:493 E:496 ||| TO
the  ||| S:496 E:500 ||| DT
criteria  ||| S:500 E:509 ||| NNS
of  ||| S:509 E:512 ||| IN
International  ||| S:512 E:526 ||| NNP
Union  ||| S:526 E:532 ||| NNP
of  ||| S:532 E:535 ||| IN
Immunological  ||| S:535 E:549 ||| NNP
Societies ||| S:549 E:558 ||| NNP
,  ||| S:558 E:560 ||| ,
who  ||| S:560 E:564 ||| WP
were  ||| S:564 E:569 ||| VBD
referred  ||| S:569 E:578 ||| VBN
to  ||| S:578 E:581 ||| TO
the  ||| S:581 E:585 ||| DT
Children ||| S:585 E:593 ||| NNP
's  ||| S:593 E:596 ||| POS
Medical  ||| S:596 E:604 ||| NNP
Center  ||| S:604 E:611 ||| NNP
in  ||| S:611 E:614 ||| IN
Tehran ||| S:614 E:620 ||| NNP
,  ||| S:620 E:622 ||| ,
Iran ||| S:622 E:626 ||| NNP
,  ||| S:626 E:628 ||| ,
between  ||| S:628 E:636 ||| IN
March  ||| S:636 E:642 ||| NNP
2006  ||| S:642 E:647 ||| CD
and  ||| S:647 E:651 ||| CC
March  ||| S:651 E:657 ||| NNP
2013  ||| S:657 E:662 ||| CD
were  ||| S:662 E:667 ||| VBD
enrolled  ||| S:667 E:676 ||| VBN
in  ||| S:676 E:679 ||| IN
this  ||| S:679 E:684 ||| DT
retrospective  ||| S:684 E:698 ||| JJ
cohort  ||| S:698 E:705 ||| JJ
study ||| S:705 E:710 ||| NN
.  ||| S:710 E:712 ||| .
Three-hundred  ||| S:712 E:726 ||| NNP
and  ||| S:726 E:730 ||| CC
seven  ||| S:730 E:736 ||| CD
PID  ||| S:736 E:740 ||| NN
patients  ||| S:740 E:749 ||| NNS
were  ||| S:749 E:754 ||| VBD
investigated ||| S:754 E:766 ||| VBN
.  ||| S:766 E:768 ||| .
Predominantly  ||| S:768 E:782 ||| RB
antibody  ||| S:782 E:791 ||| JJ
deficiencies  ||| S:791 E:804 ||| NNS
were  ||| S:804 E:809 ||| VBD
the  ||| S:809 E:813 ||| DT
most  ||| S:813 E:818 ||| RBS
common  ||| S:818 E:825 ||| JJ
group  ||| S:825 E:831 ||| NN
of  ||| S:831 E:834 ||| IN
PID  ||| S:834 E:838 ||| NNP
observed  ||| S:838 E:847 ||| VBD
in  ||| S:847 E:850 ||| IN
118  ||| S:850 E:854 ||| CD
cases  ||| S:854 E:860 ||| NNS
( ||| S:860 E:861 ||| -LRB-
38.4 ||| S:861 E:865 ||| CD
% ||| S:865 E:866 ||| NN
) ||| S:866 E:867 ||| -RRB-
,  ||| S:867 E:869 ||| ,
followed  ||| S:869 E:878 ||| VBN
by  ||| S:878 E:881 ||| IN
the  ||| S:881 E:885 ||| DT
well-defined  ||| S:885 E:898 ||| JJ
syndromes  ||| S:898 E:908 ||| NN
with  ||| S:908 E:913 ||| IN
immunodeficiency  ||| S:913 E:930 ||| NN
in  ||| S:930 E:933 ||| IN
52  ||| S:933 E:936 ||| CD
( ||| S:936 E:937 ||| -LRB-
16.9 ||| S:937 E:941 ||| CD
% ||| S:941 E:942 ||| NN
) ||| S:942 E:943 ||| -RRB-
,  ||| S:943 E:945 ||| ,
congenital  ||| S:945 E:956 ||| JJ
defects  ||| S:956 E:964 ||| NNS
of  ||| S:964 E:967 ||| IN
phagocyte  ||| S:967 E:977 ||| NN
in  ||| S:977 E:980 ||| IN
45  ||| S:980 E:983 ||| CD
( ||| S:983 E:984 ||| -LRB-
14.7 ||| S:984 E:988 ||| CD
% ||| S:988 E:989 ||| NN
) ||| S:989 E:990 ||| -RRB-
,  ||| S:990 E:992 ||| ,
combined  ||| S:992 E:1001 ||| JJ
immunodeficiencies  ||| S:1001 E:1020 ||| NN
in  ||| S:1020 E:1023 ||| IN
36  ||| S:1023 E:1026 ||| CD
( ||| S:1026 E:1027 ||| -LRB-
11.7 ||| S:1027 E:1031 ||| CD
% ||| S:1031 E:1032 ||| NN
) ||| S:1032 E:1033 ||| -RRB-
,  ||| S:1033 E:1035 ||| ,
autoinflammatory  ||| S:1035 E:1052 ||| JJ
disorders  ||| S:1052 E:1062 ||| NNS
in  ||| S:1062 E:1065 ||| IN
34  ||| S:1065 E:1068 ||| CD
( ||| S:1068 E:1069 ||| -LRB-
11.4 ||| S:1069 E:1073 ||| CD
% ||| S:1073 E:1074 ||| NN
) ||| S:1074 E:1075 ||| -RRB-
,  ||| S:1075 E:1077 ||| ,
immune  ||| S:1077 E:1084 ||| JJ
dysregulation  ||| S:1084 E:1098 ||| NN
in  ||| S:1098 E:1101 ||| IN
11  ||| S:1101 E:1104 ||| CD
( ||| S:1104 E:1105 ||| -LRB-
3.6 ||| S:1105 E:1108 ||| CD
% ||| S:1108 E:1109 ||| NN
) ||| S:1109 E:1110 ||| -RRB-
,  ||| S:1110 E:1112 ||| ,
complement  ||| S:1112 E:1123 ||| JJ
deficiencies  ||| S:1123 E:1136 ||| NNS
in  ||| S:1136 E:1139 ||| IN
7  ||| S:1139 E:1141 ||| CD
( ||| S:1141 E:1142 ||| -LRB-
2.3 ||| S:1142 E:1145 ||| CD
% ||| S:1145 E:1146 ||| NN
) ||| S:1146 E:1147 ||| -RRB-
,  ||| S:1147 E:1149 ||| ,
and  ||| S:1149 E:1153 ||| CC
defects  ||| S:1153 E:1161 ||| NNS
in  ||| S:1161 E:1164 ||| IN
innate  ||| S:1164 E:1171 ||| JJ
immunity  ||| S:1171 E:1180 ||| NN
in  ||| S:1180 E:1183 ||| IN
3  ||| S:1183 E:1185 ||| CD
( ||| S:1185 E:1186 ||| -LRB-
1 ||| S:1186 E:1187 ||| CD
% ||| S:1187 E:1188 ||| NN
) ||| S:1188 E:1189 ||| -RRB-
.  ||| S:1189 E:1191 ||| .
Selective  ||| S:1191 E:1201 ||| JJ
IgA  ||| S:1201 E:1205 ||| JJ
deficiency  ||| S:1205 E:1216 ||| NN
was  ||| S:1216 E:1220 ||| VBD
the  ||| S:1220 E:1224 ||| DT
most  ||| S:1224 E:1229 ||| RBS
prevalent  ||| S:1229 E:1239 ||| JJ
disorder  ||| S:1239 E:1248 ||| NN
which  ||| S:1248 E:1254 ||| WDT
affected  ||| S:1254 E:1263 ||| VBD
46  ||| S:1263 E:1266 ||| CD
individuals  ||| S:1266 E:1278 ||| NNS
( ||| S:1278 E:1279 ||| -LRB-
14.9 ||| S:1279 E:1283 ||| CD
% ||| S:1283 E:1284 ||| NN
) ||| S:1284 E:1285 ||| -RRB-
.  ||| S:1285 E:1287 ||| .
The  ||| S:1287 E:1291 ||| DT
median  ||| S:1291 E:1298 ||| JJ
diagnostic  ||| S:1298 E:1309 ||| JJ
delay  ||| S:1309 E:1315 ||| NN
was  ||| S:1315 E:1319 ||| VBD
15  ||| S:1319 E:1322 ||| CD
months ||| S:1322 E:1328 ||| NNS
.  ||| S:1328 E:1330 ||| .
Increased  ||| S:1330 E:1340 ||| JJ
awareness  ||| S:1340 E:1350 ||| NN
and  ||| S:1350 E:1354 ||| CC
availability  ||| S:1354 E:1367 ||| NN
of  ||| S:1367 E:1370 ||| IN
diagnostic  ||| S:1370 E:1381 ||| JJ
tests  ||| S:1381 E:1387 ||| NNS
could  ||| S:1387 E:1393 ||| MD
result  ||| S:1393 E:1400 ||| VB
in  ||| S:1400 E:1403 ||| IN
the  ||| S:1403 E:1407 ||| DT
better  ||| S:1407 E:1414 ||| JJR
recognition  ||| S:1414 E:1426 ||| NN
of  ||| S:1426 E:1429 ||| IN
more  ||| S:1429 E:1434 ||| RBR
undiagnosed  ||| S:1434 E:1446 ||| JJ
PID  ||| S:1446 E:1450 ||| NN
cases  ||| S:1450 E:1456 ||| NNS
and  ||| S:1456 E:1460 ||| CC
a  ||| S:1460 E:1462 ||| DT
decrease  ||| S:1462 E:1471 ||| NN
in  ||| S:1471 E:1474 ||| IN
diagnostic  ||| S:1474 E:1485 ||| JJ
delay ||| S:1485 E:1490 ||| NN
.  ||| S:1490 E:1492 ||| .
